The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Neurocrine Biosciences begins phase 3 registrational study of osavampator as an adjunctive therapy to treat major depressive disorder: San Diego Wednesday, January 29, 2025, 18:00 ...

People with bipolar I disorder have had at least one manic episode preceded or followed by hypomanic or major depressive ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Mind Medicine (MNMD – Research Report). The associated price ...